MSD (UK) Limited (United Kingdom)

Recent papers from MSD (UK) Limited (United Kingdom)

1. Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort StudyeJHaem · 2026
2. Imipenem/Cilastatin/Relebactam for MDR Pseudomonas aeruginosa: Real-World Clinical Effectiveness and Contexts of UseAntibiotics · 2026
3. Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trialsEuropean Heart Journal · 2026
4. Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trialsEuropean Heart Journal · 2026
5. The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UKEuropean Heart Journal · 2026
6. Real-world treatment patterns and outcomes in patients with chronic lymphocytic leukemia previously exposed to both covalent Bruton's tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor therapyHaematologica · 2026
7. Real-world treatment patterns, healthcare resource utilization, and costs associated with high-risk endometrial cancer in England: a retrospective cohort studyJournal of Medical Economics · 2026
8. Evaluating potential sources of bias in linear growth rate analysis of renal tumors: case study in Von-Hippel Lindau diseaseAmerican Journal of Epidemiology · 2026
9. Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and WalesTherapeutic Advances in Infectious Disease · 2026
10. From Joint Clinical Assessment to National Decisions: EU HTA Implementation and Implications for Patient AccessJournal of Market Access & Health Policy · 2026
11. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United StatesJournal of Medical Economics · 2026
12. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin TherapiesJournal of the American College of Cardiology · 2026
13. Clinical Outcomes and Healthcare Resource Utilization Results Among Hospitalized Adults with Cystic Fibrosis Treated with Ceftolozane/Tazobactam: A SPECTRA Real-World Subgroup AnalysisAntibiotics · 2026
14. The Discovery Process Chemistry (DPC) Model: A Cross-Pharma PerspectiveOrganic Process Research & Development · 2026
15. Trajectories of cervical cancer patients through the health systems of Colombia and GuatemalaJournal of Clinical Oncology · 2026
16. Health-related quality of life in COVID-19 in the United Kingdom: a vignette studyHealth Economics Review · 2026
17. Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimensBlood Neoplasia · 2026
18. Extrapolation of Time-to-Event Survival Outcomes of Histology-Independent Therapies Using a Bayesian Hierarchical ModelMedical Decision Making · 2026
19. Abstract 5134: In vitro and in vivo biology characterization of two novel inhibitors targeting the different domains of DNA polymerase theta (Polθ)Cancer Research · 2026
20. Modelling the time to cervical cancer elimination in England: strategies for achieving elimination by 2040SHILAP Revista de lepidopterología · 2026